Company: MDCXW
Filing Date: 2025-03-28
Form Type: 253G2
Source: 0001062993-25-006502
Chunk: 152

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-28
Form: 253G2
Chunk 152
---
2030 Warrants. As to any fraction of a share which the holder would otherwise be entitled to purchase upon such exercise, we shall, at our election, either pay a cash adjustment in respect of such fraction in an amount equal to such fraction multiplied by the exercise price of the 2030 Warrants or round the number of shares to be received by the holder up to the next whole number.

The 2030 Warrants will contain a contractual provision stating that all questions concerning the construction, validity, enforcement and interpretation of the 2030 Warrants are governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law.

This summary of the 2030 Warrants is not complete, and is qualified in its entirety by, the full text of the 2030 Warrants and Warrant Agency Agreement in respect of the 2030 Warrants, copies of which have been filed with the SEC as exhibits to this annual report and incorporated herein by reference.

<div align='center'>7

MEDICUS PHARMA LTD.

(the "Company")

INSIDER TRADING POLICY</div>

1.PURPOSE

1.1The trading of securities is governed by extensive and complex securities legislation, the fundamental premise of which is that everyone investing in securities should have equal access to information that may affect their investment decisions.

1.2The purpose of this Insider Trading Policy is to ensure that the directors, officers and other employees of the Company do not trade in securities of the Company while in possession of material information affecting the business or affairs of the Company that has not been generally disclosed to the public which would, itself, undermine the principle purpose of securities legislation relating to insider trading (within the meaning set forth below).

1.3This Insider Trading Policy (this "Policy") is intended not only to ensure that the directors, officers and other employees of the Company act, but also that they are perceived to act, in accordance with applicable laws and high standards of ethical and professional behaviour in order to protect the reputation of the Company.

2.PROHIBITED TRADING

2.1Trading While In Possession of Undisclosed Material Information: Securities legislation prohibits a reporting issuer and any person in a "special relationship" with a reporting issuer (which includes, but is not limited to, directors, officers and other employees) from trading in securities of the reporting issuer (including the granting of stock options) with knowledge of a "material fact" , a "material change" or